Prostate-specific antigen (PSA) is a biomarker for prostate cancer, and studies have found that certain serum miRNAs can better distinguish benign prostate hyperplasia from prostate cancer [23, 24] comparing to PSA. The gene discussed is KLK3; the disease is prostate carcinoma.